The DOI matches its OpenAlex record; 61 of the 61 references it cites were found in a registry or an index.
Diabetic Dyslipidemia: Causes and Consequences
Abstract
More cardiovascular disease occurs in patients with either type 1 or 2 diabetes. The link between diabetes and atherosclerosis is, however, not completely understood. Among the metabolic abnormalities that commonly accompany diabetes are disturbances in the production and clearance of plasma lipoproteins. Moreover, development of dyslipidemia may be a harbinger of future diabetes. A characteristic pattern, termed diabetic dyslipidemia, consists of low high density lipoprotein (HDL), increased triglycerides, and postprandial lipemia. This pattern is most frequently seen in type 2 diabetes and may be a treatable risk factor for subsequent cardiovascular disease. The pathophysiological alterations in diabetes that lead to this dyslipidemia will be reviewed in this article. Defects in insulin action and hyperglycemia could lead to changes in plasma lipoproteins in patients with diabetes. Alternatively, especially in the case of type 2 diabetes, the obesity/insulin-resistant metabolic disarray that is at the root of this form of diabetes could, itself, lead to lipid abnormalities exclusive of hyperglycemia. Type 1 diabetes, previously termed insulin-dependent diabetes mellitus, provides a much clearer understanding of the relationship among diabetes, insulin deficiency, and lipid/lipoprotein metabolism. In poorly controlled type 1 diabetes and even ketoacidosis, hypertriglyceridemia and reduced HDL commonly occur (1). Replacement of insulin in these patients may correct these abnormalities, and well controlled diabetics may have increased HDL and lower than average triglyceride levels. The lipoprotein abnormalities commonly present in type 2 diabetes, previously termed noninsulin-dependent diabetes mellitus, include hypertriglyceridemia and reduced plasma HDL cholesterol. In addition, low density lipoprotein (LDL) are converted to smaller, perhaps more atherogenic, lipoproteins termed small dense LDL (2). In contrast to type 1 diabetes, this phenotype is not usually fully corrected with glycemic control. Moreover, this dyslipidemia often is found in prediabetics, patients with insulin resistance but normal indexes of plasma glucose (3). Therefore, abnormalities in insulin action and not hyperglycemia per se are associated with this lipid abnormality. In support of this hypothesis, some thiazoladinediones improve insulin actions on peripheral tissues and lead to a greater improvement in lipid profiles than seen with other glucose-reducing agents (4). Several factors are likely to be responsible for diabetic dyslipidemia: insulin effects on liver apoprotein production, regulation of lipoprotein lipase (LpL), actions of cholesteryl ester transfer protein (CETP), and peripheral actions of insulin on adipose and muscle. A number of studies using tracer kinetics in humans have demonstrated that liver production of apolipoprotein B (apoB), the major protein component of very low density lipoprotein (VLDL) and LDL, is increased in type 2 diabetes. ApoB is a large (>500-kDa) protein whose production is not modulated at the level of protein synthesis. In animals and cultured liver cells, transcription of the apoB gene is not remarkably altered by dietary changes and diabetes. Rather, a large amount of newly synthesized protein is degraded either during or immediately after translation. This degradation is prevented when lipid is added to the protein; this occurs via the actions of microsomal triglyceride transfer protein (the protein that is defective in patients with apobetalipoproteinemia). Thus, lipid regulates apoB production. Increased lipolysis in adipocytes due to poor insulinization results in increased fatty acid release from fat cells. The ensuing increase in fatty acid transport to the liver, which is a common abnormality seen in insulin-resistant diabetes, may cause an increase in VLDL secretion. Tissue culture (5), animal experiments (6), and human studies (7) suggest that fatty acids modulate liver apoB secretion. A second regulatory process may be a direct effect of insulin on liver production of apoB and other proteins involved in degradation of circulating lipoproteins. In some studies insulin directly increased degradation of newly synthesized apoB (8). Therefore, insulin deficiency or hepatic insulin resistance may increase the secretion of apoB. Insulin may modulate the production of a number of other proteins that affect circulating levels of lipoproteins. These include apoCIII (9), a small apoprotein that may increase VLDL by preventing the actions of LpL and inhibiting lipoprotein uptake via the LDL receptor-related protein (LRP). Hepatic lipase is an enzyme synthesized by hepatocytes that hydrolyzes phospholipids and triglycerides on HDL and remnant lipoproteins. Some (10, 11), but not all (12), studies suggest that this enzyme is reduced by insulin deficiency. One effect of hepatic lipase deficiency is to decrease the clearance of postprandial remnant lipoproteins (see below). LpL is the major enz
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J., Chow, W. S., Stern, D., & Schmidt, A. M. (1998) · Nature Medicine · doi:10.1038/2012 · Cited by 1,104
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Self-citationLemieux, I., Pascot, A., Couillard, C., Lamarche, B., Tchernof, A., Alméras, N., Bergeron, J., Gaudet, D., Tremblay, G., Prud’homme, D., et al. (2000) · Circulation · doi:10.1161/01.cir.102.2.179 · Cited by 937
Gardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism
Febbraio, M., Abumrad, N. A., Hajjar, D. P., Sharma, K., Cheng, W., Pearce, S. F. A., & Silverstein, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19055 · Cited by 769
Lewis, G. F., Uffelman, K. D., Szeto, L. W., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 502
Haffner, S. M., Mykkänen, L., Festa, A., Burke, J. P., & Stern, M. P. (2000) · Circulation · doi:10.1161/01.cir.101.9.975 · Cited by 457
Dixon, J. L., Furukawa, S., & Ginsberg, H. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67758-6 · Cited by 418
Lamarche, B. (1998) · JAMA · doi:10.1001/jama.279.24.1955 · Cited by 417
Jiang, X.-C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., & Tall, A. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5578 · Cited by 394
Postprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360
Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance
Taghibiglou, C., Carpentier, A., Van Iderstine, S. C., Chen, B., Rudy, D., Aiton, A., Lewis, G. F., & Adeli, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8416 · Cited by 347
Kozarsky, K. F., Donahee, M. H., Glick, J. M., Krieger, M., & Rader, D. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.3.721 · Cited by 337
Arai, T., Wang, N., Bezouevski, M., Welch, C., & Tall, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2366 · Cited by 312
Insulin resistance and lipid metabolism
Howard, B. V. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00355-0 · Cited by 261
Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes.
Sparks, J. D., & Sparks, C. E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38966-5 · Cited by 253
Semenkovich, C. F., Wims, M., Noe, L., Etienne, J., & Chan, L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81898-1 · Cited by 249
THE EFFECT OF ALLOXAN DIABETES ON EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN THE RABBIT
Duff, G. L., & McMillan, G. C. (1949) · Journal of Experimental Medicine · doi:10.1084/jem.89.6.611 · Cited by 248
Horowitz, B. S., Goldberg, I. J., Merab, J., Vanni, T. M., Ramakrishnan, R., & Ginsberg, H. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116384 · Cited by 231
Self-citationHeterogeneity of plasma low-density lipoproteins and atherosclerosis risk
Krauss, R. M. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199410000-00005 · Cited by 230
LEWIS, G. F., O'MEARA, N. M., SOLTYS, P. A., BLACKMAN, J. D., IVERIUS, P. H., PUGH, W. L., GETZ, G. S., & POLONSKY, K. S. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-4-934 · Cited by 202
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184
Increased atherosclerosis in streptozotocin-induced diabetic mice.
Kunjathoor, V. V., Wilson, D. L., & LeBoeuf, R. C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118604 · Cited by 182
Ginsberg, H. N. (1996) · Diabetes · doi:10.2337/diab.45.3.s27 · Cited by 168
Insulin‐induced dephosphorylation of hormone‐sensitive lipase
Strålfors, P., & Honnor, R. C. (1989) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1989.tb14842.x · Cited by 150
Dyslipidemia and Vascular Dysfunction in Diabetic Pigs Fed an Atherogenic Diet
Dixon, J. L., Stoops, J. D., Parker, J. L., Laughlin, M. H., Weisman, G. A., & Sturek, M. S. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.12.2981 · Cited by 149
Taskinen, M., & Nikkil�, E. A. (1979) · Diabetologia · doi:10.1007/bf01236268 · Cited by 146
The ABCs of cholesterol efflux
Young, S. G., & Fielding, C. J. (1999) · Nature Genetics · doi:10.1038/11878 · Cited by 139
Nordestgaard, B. G., Stender, S., & Kjeldsen, K. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.4.421 · Cited by 137
Hayek, T., Azrolan, N., Verdery, R. B., Walsh, A., Chajek‐Shaul, T., Agellon, L. B., Tall, A. R., & Breslow, J. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116683 · Cited by 133
de Man, F. H. A. F., Cabezas, M. C., van Barlingen, H. H. J. J., Erkelens, D. W., & de Bruin, T. W. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.114256.x · Cited by 124
Clay, M. A., Newnham, H. H., & Barter, P. J. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.2.415 · Cited by 108
Reaven, P. D., Merat, S., Casanada, F., Sutphin, M. S., & Palinski, W. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.2250 · Cited by 104
Véniant, M. M., Pierotti, V, Newland, D., Cham, C. M., Sanan, D. A., Walzem, R. L., & Young, S. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119511 · Cited by 100
Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H
Ishida, B., Blanche, P. J., Nichols, A., Yashar, M., & Paigen, B. J. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42043-7 · Cited by 94
LDL Heterogeneity and Atherosclerosis in Nonhuman Primatesa
Rudel, L. L., Bond, M. G., & Bullock, B. C. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb11864.x · Cited by 86
Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 86
Self-citationLipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.
Goldberg, I. J., Le, N., Ginsberg, H. N., Krauss, R. M., & Lindgren, F. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113354 · Cited by 74
Self-citationRuotolo, G., Parlavecchia, M., Taskinen, M., Galimberti, G., Zoppo, A., Le, N., Ragogna, F., Micossi, P., & Pozza, G. (1994) · Diabetes Care · doi:10.2337/diacare.17.1.6 · Cited by 71
Ginsberg, H. N., Plutzky, J., & Sobel, B. E. (1999) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/204748739900600512 · Cited by 70
Campos, H., Bailey, S. M., Gussak, L. S., Siles, X., Ordovas, J. M., & Schaefer, E. J. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.4.1077 · Cited by 68
Regulation of lipoprotein lipase in the diabetic rat.
Tavangar, K., Murata, Y., Pedersen, M. E., Goers, J. F., Hoffman, A. R., & Kraemer, F. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116039 · Cited by 68
Yost, T. J., Froyd, K. K., Jensen, D. R., & Eckel, R. H. (1995) · Metabolism · doi:10.1016/0026-0495(95)90193-0 · Cited by 67
Marshall, B. A., Tordjman, K. M., Host, H. H., Ensor, N. J., Kwon, G., Marshall, C. A., Coleman, T., McDaniel, M. L., & Semenkovich, C. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27426 · Cited by 66
Insulin-independent diabetes: A defect in the activity of lipoprotein lipase in adipose tissue
Taylor, K. G., Galton, D. J., & Holdsworth, G. (1979) · Diabetologia · doi:10.1007/bf01223620 · Cited by 59
Lipid intervention trials in diabetes.
Steiner, G. A. (2000) · PubMed · Cited by 56
Kako, Y., Huang, L., Yang, J., Katopodis, T., Ramakrishnan, R., & Goldberg, I. J. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32093-9 · Cited by 49
Self-citationLitwak, K. N., Cefalu, W. T., & Wagner, J. D. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90349-3 · Cited by 43
Misra, U. K., Gawdi, G., Gonzalez–Gronow, M., & Pizzo, S. V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25785 · Cited by 40
Julien, P., Void, M.-C., Gaudet, D., Gagné, C., Lévesque, G., Després, J., Cadelis, F., Brun, L., Nadeau, A., & Murthy, M. R. V. (1997) · Diabetes · doi:10.2337/diab.46.12.2063 · Cited by 39
Pathophysiology and management of low high-density lipoprotein cholesterol
Rader, D. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00210-6 · Cited by 23
Lewis, G. F., O’Meara, N., Cabana, V. G., Blackman, J. D., Pugh, W. L., Druetzler, A. F., Lukens, J. R., Getz, G. S., & Polonsky, K. S. (1991) · Diabetologia · doi:10.1007/bf00405084 · Cited by 21
Matsumoto, T., Ohashi, Y., Yamada, N., & Kikuchi, M. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1062 · Cited by 15
Cited by
Association between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280
Type 2 Diabetes in Children and Adolescents
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.035 · Cited by 926
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP
Lin, J., Yang, R., Tarr, P. T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005) · Cell · doi:10.1016/j.cell.2004.11.043 · Cited by 625
Metadata
- Authors
- Goldberg, I. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2001-03-01
- Volume
- 86
- Issue
- 3
- Pages
- 965-971
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2003771230
- Cited by
- 643
- References
- 61
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.